References
- Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001; 137: 581–93
- Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma: Multinational phase II–III trial results. J Clin Oncol. 2001; 19: 2456–71
- Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: A retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49: 873–8
- Zackheim HS, Kashani-Sabet M, Hwang ST. Low dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients. J Am Acad Dermatol. 1996; 34: 626–31
- Wright JC, Lyons MM, Walker DG, Golomb FM, Gumport SL, Medrek TJ. Observations on the use of cancer chemotherapeutic agents in patients with mycosis fungoides. Cancer. 1964; 17: 1045–62
- McDonald CJ, Bertino JR. Treatment of mycosis fungoides lymphoma effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep. 1978; 62: 1009–14
- Schappell DL, Alper JC, McDonald CJ. Treatment of advanced mycosis fungoides and Sezary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermatol. 1995; 131: 307–13
- Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL. [Treatment of cutaneous T-cell lymphomas with bexarotene.] Actas. Dermosifiliogr. 2005; 96: 669–73
- Talpur R, Ward S, Apisarnthanarax N. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002; 47: 672–84
- Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, et al. Results of phase II trial of oral bexarotene (Tagretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007; 109: 1799–803
- Foss F, Demierre MF, Divenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005; 106: 454–7
- Ortiz-Romero PL, Sánchez-Largo ME, Sanz H, García-Romero D, Rosales B, Valverde R, et al. Treatment of mycosis fungoides with PUVA and bexarotene. Actas Dermosifiliogr. 2006; 97: 311–18
- Tsirigotis P, Pappa V, Papageorgiou S, Kapsimali V, Giannopoulou V, KaitsaI, et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sezary syndrome. Br J Dermatol. 2007; 156: 1379–81
- Common terminology criteria for adverse events (CTCAE). V. 3.0. Published date: August 9, 2006, web accessed 12 Nov 2008:. http://ctep.cancer.gov/forms/CTCAEv3.pdf.